Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]

Core Insights - Nuwellis, Inc. reported steady performance and key milestones in critical care, pediatrics, and hospital-based outpatient therapy, focusing on cardiorenal conditions [1][3] Financial Performance - Total revenue for Q3 2025 was $2.2 million, a decrease of 6% year-over-year but an increase of 29% sequentially from Q2 2025 [4][7] - On a pro-forma basis, revenue grew approximately 7% year-over-year after excluding one-time revenue from SeaStar Medical [4][7] - Gross margin was 65.2%, down from 70.0% in the prior year quarter, attributed to unfavorable manufacturing utilization [5] - Operating expenses totaled $4.1 million, up 30% year-over-year, reflecting investments in rebuilding the U.S. sales force and sustaining engineering [6] - The operating loss was $2.7 million, compared to $1.5 million in the previous year [6][19] Business Developments - The company launched a new 24-hour circuit and dual-lumen extended-length catheter, enhancing provider flexibility in therapy delivery [7] - The first Aquadex therapies were delivered in a hospital-based outpatient setting, marking a significant step in expanding access to ultrafiltration therapy [7] - Pediatric product development accelerated through an NIH-funded collaboration for the Vivian™ pediatric CRRT system [7] - Nuwellis initiated a manufacturing transition to KDI Precision Manufacturing and began winding down international operations to focus on U.S. market growth [7] Cash Position - The company ended the quarter with $3.1 million in cash and cash equivalents and remains debt-free [6][19]